Psilera Closes Oversubscribed $8.8M Seed Funding Round to Accelerate Neuroplastogen PSIL-006 Into the Clinic

TAMPA, Fla., May 28, 2026 /PRNewswire/ -- Psilera Inc. ("Psilera"), a leading biopharmaceutical company pioneering next-generation neuroplastogens and psychedelic therapies, today announced the successful closing of an oversubscribed $8.8 million Series Seed extension funding round led by...